The Benova Mouth Rinse System demonstrated a significant 17% reduction in the inflammatory marker TNF-alpha within just two minutes of application, according to research presented by Daniel J. Gibson, PhD, at the 2025 Diabetic Limb Salvage Conference. This finding holds particular importance for the millions affected by oral mucositis, a condition impacting 51% of chemotherapy patients, and recurrent aphthous stomatitis, prevalent in 25% of the general population. The study's results suggest a non-pharmaceutical approach to managing painful oral inflammation, which could alter treatment protocols for these widespread conditions.
Gibson's research, conducted at the University of Alabama Capstone College of Nursing, employed an in vitro model to simulate inflamed oral mucosa. This methodology showcased the rinse's rapid anti-inflammatory effects achieved without reliance on lidocaine, steroids, or prescription drugs. 'These results reflect Benova's potential to relieve pain and support healing through targeted cytokine reduction,' stated Gibson. The mechanism focuses on directly addressing inflammatory pathways, which is a critical factor in the pain and tissue damage associated with oral ulcerations.
Bill Kling, co-founder of Benova, emphasized the correlation between these laboratory findings and anecdotal reports from users who describe quick pain relief and healing of oral ulcers. The Diabetic Limb Salvage Conference, renowned for its focus on advanced wound care and tissue regeneration, provided a fitting venue for these results, linking oral mucosal health to broader principles of healing. The Benova Mouth Rinse System is engineered to deliver immediate symptomatic relief for conditions like stomatitis and oral mucositis, positioning it as a tool for a diverse group of healthcare professionals including oncologists, dentists, and periodontists. For comprehensive details on the study's methodology and outcomes, the full scientific rationale and poster findings are accessible here.
The implications of this research are substantial for patient care, offering a potential alternative or adjunct to current treatments that often involve medications with side effects or limited efficacy. By providing a rapid reduction in a key inflammatory marker, the rinse addresses a fundamental component of these painful conditions. This development could lead to improved quality of life for patients undergoing chemotherapy or those suffering from chronic mouth ulcers, supporting faster healing and reducing discomfort through a targeted, non-systemic intervention.
